Introduction

Acute kidney injury (AKI) is a complex syndrome that occurs under wide variety of conditions, with manifestations ranging from a small increase in serum creatinine (SCr) to anuric renal failure. The clinical outcomes of this disease range from full recovery to death and might include the development of chronic kidney disease and progression to renal replacement therapy (RRT) [1]. Most studies have diagnosed AKI according to changes in SCr, absolute levels of creatinine, changes in urine output or the need for RRT [2–6]. AKI is a common complication in critically ill patients, which generates increased hospital costs [7] and is associated with high mortality as an independent predictor of death [8].

Multinational and multicenter epidemiological studies indicate that sepsis is currently the most common cause of AKI in intensive care, followed by AKI associated with cardiac surgery [9]. Minimal changes in postoperative SCr have been associated with a significant reduction in short and long-term survival [10]. The elevation of SCr might be associated with increased morbidity and mortality, even when these changes do not exceed normal values [11].

Several consensus definitions have been developed to provide uniform criteria for the diagnosis of AKI, facilitating comparisons between studies and the development of quantitative research. In 2004, the “Acute Dialysis Quality Initiative (ADQI)” proposed guidelines, called RIFLE criteria (Risk, Injury, Failure, Loss and End-stage Kidney Disease) [12], subsequently modified by the “Acute Kidney Injury Network” (AKIN, which included the ADQI) [13–15]. More recently, the AKI study group, “Kidney Disease: Improving Global Outcomes (KDIGO)”’s modified definition, harmonizing the differences between the RIFLE and AKIN definitions [1]. These definitions were independently validated in multiple studies and are now widely accepted [2,16].

The aim of the present study was to apply the AKI criteria, based on KDIGO classification, in a population of patients undergoing cardiac surgery (coronary artery bypass grafting...
(CABG) or cardiac valve surgery (CVS)] to evaluate the impact of this feature as a predictor of 30-day mortality.

**Materials and Methods**

**Patient Selection**

We conducted a single-center study. We retrospectively evaluated patients from the Cardiac Surgery Intensive Care Unit in a Brazilian Medical School facility. The demographics, type of surgery, laboratory data and preoperative, perioperative, and postoperative information were retrieved from a prospectively collected database of 2,878 patients older than 18 years and undergoing isolated CABG (1,786) or CVS (1,092) from January 2003 to June 2013. After applying the exclusion criteria (51 patients with incomplete data and 23 patients with end-stage kidney disease), a total of 2,804 patients were suitable for analysis: 1,738 (62%) patients underwent CABG, and 1,066 (38%) patients underwent CVS (Figure 1).

This study was conducted in accordance with the Declaration of Helsinki and approved through the Local Human Research Ethics Committee of São José do Rio Preto Medical School (protocol 5974/2008). The need for individual informed consent was waived, as this study was a retrospective analysis of prospectively collected data for routine care, and there was no breach of privacy or anonymity. ClinicalTrials.gov register – NCT00777465.

**Serum Creatinine Measurement**

The Jaffe colorimetric method (ADVIA 1650, Bayer, Germany) was used to measure the SCr concentration. The reference value for adults is 0.6 to 1.3 mg/dL for men and 0.6 to 1.0 mg/dL for women.

**Diagnosis and Staging of AKI (KDIGO) [1]**

AKI was defined as any of the following:

- Increase in SCr≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours;
- Increase in SCr≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days;
- AKI was also staged for severity according to the following criteria:
  - Stage 1: Increase in SCr≥0.3 mg/dL (≥26.5 μmol/L) or 1.5 to 1.9 times baseline
  - Stage 2: 2.0 to 2.9 times baseline SCr
  - Stage 3: 3.0 or more times baseline; increase in SCr≥4.0 mg/dL; or initiation of renal replacement therapy

**Data Analysis**

Serum creatinine was measured daily in the postoperative period, according to the intensive care routine, and every 48 hours on the ward. These values were recorded until the 7th day after surgery, and the patients followed during the first 30 days of surgery. The diagnosis of AKI was based on the SCr levels recorded during the first seven days after surgery (compared with the preoperative measurement on admission to the hospital) as well as the need for RRT, and the patients were classified as no AKI (KDIGO 0) or AKI (KDIGO 1–3). Due to the lack of data on urine output, only SCr was used to determine the AKI categories. The glomerular filtration rate (eGFR) was estimated using the Cockcroft-Gault equation [17], and consulting nephrologists in charge of the patient’s care (available 24/7) established the need for RRT. The risk of postoperative death was estimated using EuroSCORE [18,19], in the absence of a specific tool for our population.

**Statistical Analysis**

The data were analyzed using the IBM SPSS Statistical Package v.20 (IBM Corporation, Armonk, NY). The variables are presented as absolute numbers and percentages and median and interquartile ranges (25th and 75th percentile) when applicable. Due to the lack of Gaussian distribution, continuous variables were compared using the nonparametric Mann-Whitney or Kruskal-Wallis tests. Chi-square or Fisher’s exact tests were used to compare categorical variables. Univariate and multivariable Cox proportional hazards models (stepwise backward elimination method) were used to determine the association between AKI and mortality at 30 days. The model was adjusted for age (years), gender (reference – male gender), type of surgery (reference – CVS), body mass index (kg/m²), diabetes mellitus (reference – non-diabetic), left ventricular function (reference – preserved left ventricular ejection fraction), cardiopulmonary bypass (CPB) times (min) and AKI (reference – KDIGO 0). The adjusted Hazard Ratio (HR) and 95% confidence intervals (95% CI) were calculated for the predictors. Cumulative

![Figure 1. 30-day mortality of cardiac surgery patients based on KDIGO classification.](https://example.com/figure1.png)
survival graphics were constructed to demonstrate the AKI impact as a predictor of 30-day mortality. P values < 0.05 were considered statistically significant (two-tailed).

Results

The demographic data and kidney function for each patient are described in Table 1. The age of the patients increased between groups as well as the percentage of patients undergoing repeat surgery and intensive care length of stay. Patients with AKI stages 1 to 3 exhibited higher EuroSCORE scores, but there was no difference in the number of patients classified as low, intermediate or high risk between the groups (P = 0.118). Thirty-six percent of the patients had preoperative chronic kidney disease (33% with an eGFR between 30–59 mL/min and 3% with an eGFR ≤ 29 mL/min).

The prevalence of AKI was 42% distributed in 35% of patients with AKI stage 1, 4% of patients with AKI stage 2 and 3% of patients with AKI stage 3. A total of 63 (2%) patients required dialysis treatment, representing sixty-five percent of stage 3 patients. The development of AKI stage 3 was most frequently observed in patients with impaired eGFR (≤ 29 mL/min) (1.7% vs. 13%) and CPB times greater than 120 minutes (13% vs. 47%; Table 2).

Patients with no postoperative AKI had a 2.2% mortality rate (36 deaths out of 1,629 patients), while patients with postoperative AKI had a 14% overall mortality rate (164 deaths out of 1,175 patients). Any degree of AKI was associated with a significant increase in the overall 30-day mortality (Table 2). The KDIGO stage 3 patients who did not require dialysis had a mortality rate of 41%, while the mortality of dialysis patients was 62%.

The subgroup analysis (CABG and CVS) showed similar results with worse mortality in patients undergoing CVS who developed AKI stage 3 (CABG – 43.1% vs. CVS – 67.4%, P = 0.017; Figure 1). Among CVS patients with AKI, the proportion of individuals subjected to repeat and multiple valve surgeries and surgery during active endocarditis increased progressively, with worsening renal function (Table 1).

Table 1. Baseline characteristics and renal function of 2,804 patients underwent cardiac surgery.

| Variable                                | All patients | KDIGO 0 | KDIGO 1 | KDIGO 2 | KDIGO 3 | P Value for all |
|-----------------------------------------|--------------|---------|---------|---------|---------|-----------------|
| Coronary artery bypass grafting         | 1,738 (62)   | 1,037 (64) | 592 (61) | 58 (58) | 51 (53) | 0.680           |
| Cardiac valve surgery                    | 1,066 (38)   | 386 (39) | 42 (42) | 46 (47) | 0.680   |
| Multiple CVS*                           | 385 (36)     | 163 (42) | 18 (43) | 23 (50) | < 0.001 |
| CVS during active IE*                   | 81 (7.6)     | 27 (7.0) | 2 (4.8) | 12 (26) | < 0.001 |
| Age (years)                             | 59 (49–66)   | 60 (52–68) | 63 (55–70) | 63 (56–70) | < 0.001 |
| Male gender                             | 1,710 (61)   | 628 (64) | 55 (55) | 64 (66) | 0.027   |
| Weight (kg)                             | 70 (61–80)   | 70 (61–80) | 72 (63–83) | 71 (60–85) | 0.218   |
| Height (m)                              | 1.65 (1.57–1.70) | 1.65 (1.58–1.70) | 1.64 (1.55–1.68) | 1.67 (1.60–1.73) | 0.112   |
| Body mass index (kg/m²)                 | 26 (23–29)   | 26 (23–29) | 28 (24–32) | 26 (23–30) | 0.004   |
| Diabetes Mellitus                       | 634 (23)     | 242 (25) | 34 (34) | 20 (21) | 0.004   |
| LV dysfunction (Moderate/severe)        | 568 (20)     | 214 (22) | 24 (24) | 26 (27) | 0.055   |
| Intra-aortic balloon pump**             | 146 (8.4)    | 58 (10) | 10 (17) | 12 (24) | < 0.001 |
| Preoperative SCR (mg/dL)                | 1.10 (0.90–1.30) | 1.10 (0.90–1.30) | 1.00 (0.80–1.28) | 1.20 (1.00–1.60) | < 0.001 |
| Preoperative eGFR (mL/min)              | 68 (53–87)   | 67 (51–88) | 69 (58–97) | 59 (39–79) | < 0.001 |
| ≥90 mL/min                              | 647 (23)     | 224 (23) | 30 (30) | 18 (19) | < 0.001 |
| 60–89 mL/min                            | 1,163 (41)   | 41 (41) | 30 (31) | < 0.001 |
| 30–59 mL/min                            | 926 (33)     | 355 (36) | 29 (29) | 36 (37) | < 0.001 |
| ≤29 mL/min                              | 68 (3.0)     | 28 (2.9) | 0 (0.0) | 13 (13) | < 0.001 |
| Immediate PO Scr (mg/dL)                | 1.10 (0.90–1.40) | 1.00 (0.90–1.20) | 1.20 (1.00–1.50) | 1.30 (1.10–1.90) | < 0.001 |
| Repeat surgery                          | 339 (12)     | 143 (15) | 19 (19) | 31 (32) | < 0.001 |
| Additive EuroScore                      | 3 (2–5)      | 4 (2–6) | 4 (2–6) | 6 (4–9) | < 0.001 |
| Low risk (<3)                           | 1,064 (38)   | 316 (32) | 28 (28) | 12 (12) | < 0.001 |
| Intermediate risk (3 to 5)              | 1,133 (40)   | 406 (42) | 35 (35) | 28 (29) | 0.118   |
| High risk (≥5)                          | 607 (22)     | 256 (26) | 37 (37) | 57 (59) | < 0.001 |
| ICU length of stay (days)               | 2 (2–5)      | 3 (2–6) | 4 (2–12) | 7 (3–17) | < 0.001 |

IQR – interquartile ranges; CVS – cardiac valve surgery; IE – infective endocarditis; LV – left ventricular; SCR – serum creatinine; eGFR – estimated glomerular filtration rate; PO – postoperative; ICU – intensive care unit.

*The percentages are related to cardiac valve surgery patients;
**The percentages are related to coronary artery bypass grafting patients.

doi:10.1371/journal.pone.0098028.t001
The multivariable Cox proportional hazards analysis showed that age (years), female gender, CPB time (min) and AKI (KDIGO stages 1–3) were independent predictors of 30-day mortality. The HR (and 95% CI) for overall mortality according to the AKI stages was (reference - KDIGO 0) stage 1, 3.35 (2.19 to 5.12); stage 2, 11.94 (7.05 to 20.20); and stage 3, 24.48 (15.05 to 39.81).

Female patients showed a 63% increased risk of death at 30 days (Table 3; Figure 2). The subgroup analysis (CABG and CVS) showed similar results, except for the increased risk of death observed in female CABG patients (data not shown). When we analyzed patients based on baseline eGFR (above and below 60 mL/min), AKI staging remained an independent predictor of death, with robust results in patients with previously preserved renal function [HR – 3.08, 17.51 and 48.86 for stages 1, 2 and 3, respectively (eGFR>60 mL/min) and HR – 3.47, 11.88 and 16.75 for stages 1, 2 and 3, respectively (eGFR<60 mL/min) – P<0.001 for all].

Robert et al. [20] evaluated more than 25,000 patients undergoing cardiac surgery and observed that 3.6% of patients developed AKI stage 3 (AKIN criteria). The univariate analysis revealed a hospital mortality rate of 36.8%, with an odds ratio of 43.8. De Santo et al. [21] evaluated 1,424 patients undergoing cardiac surgery (CABG or CVS) and reported a hospital mortality rate of 10.4%, with an odds ratio of 3.1. The multivariable Cox Regression Model, using the Multivariable Cox Proportional Hazards Model, showed that age (years), female gender, CPB time (min) and AKI (KDIGO stages 1–3) were independent predictors of 30-day mortality. The HR (and 95% CI) for overall mortality according to the AKI stages was (reference - KDIGO 0) stage 1, 3.35 (2.19 to 5.12); stage 2, 11.94 (7.05 to 20.20); and stage 3, 24.48 (15.05 to 39.81).

In the present study, we evaluated patients with AKI after cardiac surgery (CABG or CVS) to evaluate this feature as a predictor of 30-day mortality. To the best of our knowledge, this study is the largest cohort of patients with AKI after cardiac surgery assessed using KDIGO classifications and showing the impact of AKI severity (stages 1–3) as a predictor of hospital mortality. Using the Multivariable Cox Regression Model, we clearly demonstrated that the development of AKI (according to KDIGO criteria) after cardiac surgery is a strong predictor of 30-day mortality as well as age, female gender and CPB times. In our study, a wide variation was observed in patient mortality, as patients who developed stage 3 AKI (97 patients - 3%) had a hospital mortality rate of 55% and a risk of death 24.5 times greater than that of patients with no AKI.

### Table 2. Cardiopulmonary bypass times, complications and mortality of patients underwent cardiac surgery.

|                          | All patients | KDIGO 0 | KDIGO 1 | KDIGO 2 | KDIGO 3 |
|--------------------------|--------------|---------|---------|---------|---------|
| n = 2,804 (100%)         | n = 1,629 (58%) | n = 978 (35%) | n = 100 (4%) | n = 97 (3%) |
| Median (IQR) or n (%)    | Median (IQR) or n (%) | Median (IQR) or n (%) | Median (IQR) or n (%) | Median (IQR) or n (%) |
| On-pump CABG             | 2,381 (85) | 1,311 (80) | 891 (91) | 91 (91) | 88 (91) |
| Cardiopulmonary bypass time | 94 (78–113) | 90 (76–109) | 97 (80–114) | 103 (85–127) | 121 (90–155) |
| <90 min                  | 993 (41) | 619 (38) | 330 (34) | 26 (26) | 18 (19) |
| 90 to 120 min            | 932 (39) | 493 (30) | 380 (39) | 35 (35) | 24 (25) |
| >120 min                 | 465 (20) | 206 (13) | 183 (19) | 30 (30) | 46 (47) |
| Off-pump CABG            | 414 (15) | 311 (19) | 85 (9.0) | 9 (9.0) | 9 (9.0) |
| Acute atrial fibrillation| 255 (9.1) | 98 (6.0) | 108 (11) | 21 (21) | 28 (29) |
| Tracheal re-intubation up to 7th day | 183 (6.5) | 47 (2.9) | 81 (8.3) | 21 (21) | 34 (33) |
| Mechanical ventilation >24 hours | 291 (12) | 67 (4.7) | 123 (15) | 34 (40) | 67 (77) |
| 30-day mortality         | 200 (7.1) | 36 (2.2) | 80 (8.2) | 31 (31) | 53 (55) |

IQR – interquartile ranges.

### Table 3. All patients – Multivariate analysis by Cox proportional hazards models – Hazard Ratio and 95% confidence intervals for predictors of 30-day mortality after cardiac surgery.

|                          | HR (95% CI) | P Value |
|--------------------------|-------------|---------|
| Age (years)              | 1.04 (1.03–1.06) | <0.001  |
| Female gender            | 1.63 (1.22–2.17) | 0.001  |
| Cardiopulmonary bypass times (min) | 1.01 (1.00–1.01) | <0.001  |
| KDIGO 0                  | Reference    |         |
| KDIGO 1                  | 3.35 (2.19–5.12) | <0.001  |
| KDIGO 2                  | 11.94 (7.05–20.20) | <0.001  |
| KDIGO 3                  | 24.48 (15.05–39.81) | <0.001  |

HR – Hazard Ratio; CI – confidence interval.
cardiac valve surgery and observed a 43.8% hospital mortality rate in patients classified as RIFLE-Failure, with an odds ratio of 30.

Even minimal changes in postoperative SCr were associated with a significant reduction in short and long-term survival [10]. The SCr elevation might be associated with increased morbidity and mortality, even when the change did not exceed normal values [10,11]. After cardiac surgery, AKI might occur in up to 48% of patients [22] and up to 9.6% of patients require RRT, particularly those with preoperative renal dysfunction [23]. In our sample, 2% of patients (65% of those classified as KDIGO stage 3) required RRT, in the first 7 postoperative days. Epidemiological studies have reported an RRT requirement of approximately 2.6% to 4.9% [24,25]. Our lower incidence of RRT was associated with the fact that the need for dialysis treatment was evaluated only in the first seven days after surgery but the similarity of other studies suggests that although each center has different patient populations and criteria for indicating RRT, the average incidence of severe AKI requiring RRT is approximately 4% [26]. In our study, the mortality of KDIGO stage 3 patients needing RRT peaked at 62%, in contrast with the mortality of patients without postoperative AKI (2.2%). Although the mortality of patients treated with RRT after cardiac surgery declined [2], in most studies, this factor remained greater than 40% [5,16,27].

We also found that age, female gender and CPB times are predictors of 30-day mortality after cardiac surgery. Age and female gender are traditional predictors of early and late mortality after cardiac surgery and are present in most contemporary operative risk scores [28,29]. Many studies have found higher mortality rates after cardiac surgery in female gender [30–32] but not all [33–35]. The higher mortality could be explained by differences in baseline characteristics such as older age, higher body mass index, more cardiovascular risk factors and comorbidities. Considering these possible confounders, we found that female gender was an independent risk factor for 30-day mortality after cardiac surgery. Cardiopulmonary bypass times were also implied to increase mortality after cardiac surgery [36]. CPB is associated with significant hemodynamic changes, and the maintenance of cardiovascular stability during CPB requires the interplay between the function of the CPB machine and patient factors [37]. Thus, any decrease in renal perfusion during CPB, depending on its magnitude and duration, can lead to significant cellular injury [37].

Currently, only three studies have used the KDIGO classification to evaluate patients after cardiac surgery. In the first study, Ho et al. [38] evaluated the change in SCr (greater or less than 10%) during the first 6 hours after surgery in 350 patients undergoing CABG or CVS. The results showed that 14% of patients developed AKI according to the KDIGO criteria, with greater than 10% variation in SCr immediately after surgery, strongly associated with subsequent AKI after cardiac surgery. In the second study, Sampaio et al. [39] evaluated the incidence and risk factors for AKI in 321 patients after cardiac surgery according to RIFLE, AKIN and KDIGO criteria. The incidence of AKI ranged from 15–51%, and the adjusted Cox regression analysis revealed that only cases diagnosed using the KDIGO criteria remained associated with the composite endpoint of death, the requirement for RRT and prolonged hospitalization. In the last study, Bastin et al. [2] retrospectively evaluated 1,881 patients undergoing cardiac surgery, comparing RIFLE, AKIN and KDIGO classification criteria. The area under the receiver operating characteristic curve for hospital mortality was significantly higher using the AKIN classification compared with the RIFLE criteria. The incidence and outcome of AKI according to AKIN and KDIGO criteria were identical.

AKI after cardiac surgery occurs secondary to renal ischemia, resulting from heart failure, prolonged hypotension or cardiovascular collapse, interruption of renal circulation, vasopressors and “post-pump syndrome” [40]. AKI might also result from atheroembolic renal insult, hemoglobinuria or myoglobinuria, age, hyperbilirubinemia, sepsis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and the use of anti-inflammatory non-steroidal or radio-contrast dye immediately.
prior to surgery [40]. However, the most predictable risk factor for AKI is pre-existing chronic kidney disease [41]. The lack of a widely used classification for AKI in different populations compromises the understanding of the incidence, evolution and effectiveness of therapeutic interventions.

**Strength and Study Limitations**

This study is a retrospective analysis of prospectively collected single-center data. Thus, the study design did not facilitate the characterization of potential causes of postoperative AKI, such as hemodynamic, electrolyte and acid-basic disturbances and the use of nephrotoxic or vasoactive drugs. The interpretation and comparison of the results obtained in the present study with those of studies based on different AKI classifications might be impaired.

**Conclusion**

In the population evaluated in the present study, even slight changes in renal function based on KDIGO criteria were considered as independent predictors of 30-day mortality after cardiac surgery (CABG or CVS). Age, female gender and CPB times were also independent mortality predictors.

**Acknowledgments**

The authors are grateful to Prof. Suzana M. A. Lobo for her time spent reviewing our manuscript.

**Author Contributions**

Conceived and designed the experiments: MNM MAN LNM. Performed the experiments: MNM MAN LNM. Analyzed the data: MNM MAN. Contributed reagents/materials/analysis tools: MAN LNM. Wrote the paper: MNM. Contributed substantially to its revision: MAN LNM. Finalized the manuscript: MAN. Read and approved the final manuscript: MNM MAN LNM.

**References**

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2: 1–138.

2. Bastin AJ, Ostermann M, Slack AJ, Diller GP, Finney SJ, et al. (2013) Acute kidney injury after cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes classifications. J Crit Care 28(4): 389–396.

3. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Heeckowtiz A, et al. (1998) Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 128(3): 194–203.

4. Han SS, Kang KJ, Kwon SJ, Wang SJ, Shin SH, et al. (2012) Additional role of urine output criterion in defining acute kidney injury. Nephrol Dial Transplant 27(1): 161–165.

5. Schneider AG, Eastwood GM, Seevanayagam S, Matalanis G, Bellomo R (2012) A risk, injury, failure, loss, and end-stage renal failure score-based trigger for renal replacement therapy and survival after cardiac surgery. J Crit Care 27(5): 488–495.

6. Dardashti A, Erderoth P, Algotsson L, Bronndén B, Bjursten H (2013) Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery. J Thorac Cardiovasc Surg. In press.

7. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA (2008) Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 23(6): 1970–1974.

8. Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML (2009) Incidence and outcomes of acute kidney injury in intensive care units: A Veterans Administration study. Crit Care Med 37(9): 2532–2538.

9. Bellomo R (2011) Acute renal failure. Semin Respir Crit Care Med 32(5): 639–650.

10. Liotta M, Olson D, Saripaty U, Holmzjan M (2014) Minimal Changes in Postoperative Creatinine Values and Early and Late Mortality and Cardiavascular Events After Coronary Artery Bypass Grafting. Ann J Cardiol 113(1): 70–75.

11. Tolpin DA, Collard CD, Lee VV, Virani SS, Allison PM, et al. (2012) Subclinical changes in serum creatinine and mortality after coronary artery bypass grafting. J Thorac Cardiovasc Surg 143(3): 682–688.

12. Bellomo R, Ronco C, Kellum J, Mehta R, Palevsky P, et al. (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Conference on the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Med 8(4): R204–R212.

13. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, et al. (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2): R31.

14. Levin A, Warnock DG, Mehta RL, Kellum JA, Shah SV, et al. (2007) Improving Outcomes From Acute Kidney Injury: Report of an Initiative. Ann J Med Dis 58(1): 1–4.

15. Molitoris BA, Levin A, Warnock DG, Josanidh M, Mehta RL, et al. (2007) Improving Outcomes From Acute Kidney Injury. J Am Soc Nephrol 18(7): 1992–1994.

16. Engberg L, Suri RM, Li Z, Casey ET, Daly RC, et al. (2011) Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care 15(1): R16.

17. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1): 31–41.

18. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshew S, et al. (1999) European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16(1): 9–13.

19. Roques F, Nashef SA, Michel P, Gauducheau E, de Vicentis C, et al. (1999) Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15(6): 816–822.

20. Robert AM, Kramer RS, Dacey JJ, Charlesworth DC, Leavitt BJ, et al. (2010) Cardiac surgery-associated acute kidney injury: a comparison of two consensus criteria. Ann Thorac Surg 90(6): 1939–1943.

21. De Santo LS, Romano G, Galdiieri N, Buonocore M, Barancue C, et al. (2010) RIFLE criteria for acute kidney injury in valvular surgery. J Heart Valve Dis 19(1): 139–147.

22. Arnaoutakis GJ, Bihorac A, Martin TD, Hess PJ Jr, Kloeell CT, et al. (2007) RIFLE criteria for acute kidney injury in aortic arch surgery. J Thorac Cardiovasc Surg 134(6): 1554–1560.

23. Yelis M, Collins JR, Beca J (2005) Acute renal failure in patients with pre-existing renal dysfunction following coronary artery bypass grafting. Nephrology (Carlton) 10(6): 541–543.

24. Xu J, Teng J, Yang X, Shen B, Liu ZH, et al. (2012) [The risk factors and prognosis of acute kidney injury after cardiac surgery: a prospective cohort study of 4007 cases]. Zhonghua Nei Ke Za Zhi 51(12): 945–947.

25. Mehta PG, Krenn CG, Stelzer H, Lang T, Ploder J, et al. (2002) Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 30: 2051–2058.

26. Uchino S (2006) The epidemiology of acute renal failure in the world. Curr Opin Crit Care 12(6): 530–543.

27. Haase M, Bellomo R, Matalanis G, Calzavacca P, Dragan D, et al. (2009) A comparison of the RIFLE and Acute Kidney Injury Network classifications for cardiac surgery associated acute kidney injury: A prospective cohort study. J Thorac Cardiovasc Surg 138(6): 1370–1376.

28. Shahian DM, O’Brien SM, Filardo G, Ferrazzi VA, Haan CK, et al. (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1–coronary artery bypass grafting surgery. Ann Thorac Surg 88[1 Suppl]: S2–S22.

29. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, et al. (2012) EuroSCORE II. European Journal of Cardio-Thoracic Surgery 41(4): 734–744.

30. Trienekens MP, Mass AH, Timman ST, Van Swieten HA, Noyez L, et al. (2014) Sex differences in patient and procedural characteristics and early outcomes following cardiac surgery. J Cardiovasc Surg (Torino): In press.

31. Wang TK, Ramanathan T, Stewart R, Gambling G, White H (2013) Higher mortality in women undergoing coronary artery bypass grafting. N Z Med J 126(1357): 25–31.

32. Ghavriel AA, Javidalikhasri H, Maleki M, Karbassi A, Omrani G, et al. (2014) Two new mathematical models for prediction of early mortality risk in coronary artery bypass graft surgery. The Journal of Thoracic and Cardiovascular Surgery: In press.

33. Alhraim D, Tamariz MG, Sevr JY, Christakis GT, Bhutnagar G, et al. (2000) The influence of gender on the outcome of coronary artery bypass surgery. Ann Thorac Surg 70: 800–805.

34. Mickleborough LL, Carson S, Ivanov J (2003) Gender differences in quality of distal vessels: effect on results of coronary artery bypass grafting. J Thorac Cardiovasc Surg 126(4): 950–958.

35. Toumpoulis IK, Anagnostopoulous CE, Balaram SK, Rokkas CK, Swietol DG, et al. (2006) Assessment of independent predictors for long-term mortality between
women and men after coronary artery bypass grafting: are women different from men? J Thorac Cardiovasc Surg 131(2): 343–351.

36. Kumar AB, Suneja M, Bayman EO, Weide GD, Tarasi M (2012) Association between postoperative acute kidney injury and duration of cardiopulmonary bypass: a meta-analysis. J Cardiothorac Vasc Anesth 26(1): 64–69.

37. Rosner MH, Okusa MD (2006) Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 1(1): 19–32.

38. Ho J, Reslerova M, Gali B, Nickerson PW, Rush DN, et al. (2012) Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. Am J Kidney Dis 59(2): 196–201.

39. Sampaio MC, Maximo CA, Montenegro CM, Mota DM, Fernandes TR, et al. (2013) Comparison of diagnostic criteria for acute kidney injury in cardiac surgery. Arq Bras Cardiol 101(1): 18–25.

40. Olivero JJ, Olivero JJ, Nguyen PT, Kagan A (2012) Acute kidney injury after cardiovascular surgery: an overview. Methodist Debakey Cardiovasc J 8(3): 31–36.

41. Cooper WA, O’Brien SM, Thourani VH, Guyton RA, Bridges CR, et al. (2006) Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 113(8): 1063–1070.